RE:So,it's the first day of the JP Morgan Healthcare ConferenceHere is my take. Promis, probably Gail, hired Stern Investor Relations two months ago. They specialize in two things, Healthcare and Biopharma. Suzanne Messere is a Managing Director responsible for the account. Biogen/Lilly did not hit a grand slam or home run, they got to first on an infield single or error. Do not think Medicare will be approving for payment anytime soon or not at all. The game is wide open. Promis sent a significant management prescense because they are in the game. Promis investment bankers and investor relations people schedule 1 on 1 meetings. I have personally been to 20+ conferences as a SVP and CFO of a public retail company. The one on ones can include, fund managers, analysts or larger pharma companies. You are selling the story by going thru selective slides and answering questions. I would think that people would want the opportunity to meet Gail and the team. We need buyers/owners. People form opinions from these meetings. Timing is everything for our stock. It is cheap and the field is wide open for a solid or better solution, with minimal side effects. There is no carrot but your confidence in the product and potential results is the selling point. Two more things, Nick is the legacy investor relations guy and no one knows the timing of the IND filing. You may consider this post to be useless but that doesn't bother me.